Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

Annals of Oncology

Volumn 29, Issue 1, 2018, Pages 119-126

  Siena, S ^a,b   Sartore Bianchi, A ^a,b   Garcia Carbonero, R ^c   Karthaus, M ^d   Smith, D ^e   Tabernero, J ^f   Van Cutsem, E ^g,h   Guan, X ⁱ   Boedigheimer, M ⁱ   Ang, A ⁱ   Twomey, B ⁱ   Bach, B A ⁱ   Jung, A S ⁱ   Bardelli, A ^j,k  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Klinikum Neuperlach   (Germany)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ AMGEN INC   (United States)

^j CANDIOLO CANCER INSTITUTE   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Biomarkers and intervention studies; Colorectal; Gastrointestinal cancers; Panitumumab; Phase I III trials

Indexed keywords

CELL FREE DNA; DNA; IRINOTECAN; PANITUMUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL FREE NUCLEIC ACID; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MOLECULAR DYNAMICS; NEXT GENERATION SEQUENCING; ONCOGENE RAS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR GROWTH; WILD TYPE; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; GENETICS; METASTASIS; MUTATION; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CELL-FREE NUCLEIC ACIDS; COLORECTAL NEOPLASMS; HUMANS; IRINOTECAN; MUTATION; NEOPLASM METASTASIS; PANITUMUMAB; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85041197106     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx504     Document Type: Article

References (18)

1. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl JMed 2013; 369: 1023-1034.
2. Misale S, Di Nicolantonio F, Sartore-Bianchi A et al. Resistance to anti- EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014; 4: 1269-1280.
3. Diaz LA Jr, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-540.
4. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536.
5. Siravegna G, Mussolin B, Buscarino M et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21: 795-801.
6. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4: e7287.
7. Bai H, Wang Z, Chen K et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012; 30: 3077-3083.
8. Murtaza M, Dawson SJ, Tsui DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108-112.
9. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32: 579-586.
10. Siena S, Sartore-Bianchi A, Karthaus M et al. A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC). Eur J Cancer 2015; 51: S394-S395.
11. Peeters M, Kafatos G, Taylor A et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials. Eur J Cancer 2015; 51: 1704-1713.
12. Li M, Chen WD, Papadopoulos N et al. Sensitive digital quantification of DNAmethylation in clinical samples. Nat Biotechnol 2009; 27: 858-863.
13. Kim TW, Price T, Peeters M et al. Evaluation of emergent circulating tumor (ct) DNA RAS mutations in patients with metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) monotherapy from the ASPECCT study [abstract]. Eur J Cancer 2016; 59: 21.
14. Arena S, Bellosillo B, Siravegna G et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015; 21: 2157-2166.
15. Misale S, Arena S, Lamba S et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014; 6: 224ra226.
16. Stachler MD, Rinehart E, Lindeman N et al. Novel molecular insights from routine genotyping of colorectal carcinomas. HumPathol 2015; 46: 507-513.
17. Zhang BM, Aleshin A, Lin CY et al. IDH2 Mutation in a Patient with Metastatic Colon Cancer. N Engl J Med 2017; 376: 1991-1992.
18. Morelli MP, Overman MJ, Dasari A et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 2015; 26: 731-736.